827
C1-INH Therapy in Acei/Arb Acquired Angioedema
Monday, March 7, 2016
South Exhibit Hall H (Convention Center)
Vipul Jain, M.D.
Rationale:

Angiotensin Converting Enzyme Inhibitors (ACEI) are a common cause of Emergency Room presentation for angioedema. Although no treatment guidelines exist, C1 esterase inhibitor concentrate (C1-INH) is used on an off label basis for management of ACE I acquired angioedema (ACEI AAE). We are evaluating the efficacy of C1-INH in management of ACEI AAE.

Methods:

This is a retrospective chart review of treatment with C1-INH therapy for ACEI AAE. The primary end point is defined as time to symptom resolution from start of C1-INH. Exclusion criteria is angioedema from any other cause.  

Results:

8 patients, from 3 academic sites, were identified through Allergy Service consultation data and records from Diagnostic Services Manitoba, Canada from 2010-2015. Less than 20 hours from time of C1-INH infusion to resolution of angioedema was defined as a positive response to treatment1.  6/8 patients required endotracheal intubation prior to initiation of C1-INH.  4/8 patients had resolution of angioedema between 12-13.5 hours (median 12.75) and no recurrence.  One patient had transient symptom resolution in 14 hours, however, recurrence of angioedema required reintubation.  

Conclusions:

Our findings demonstrate a therapeutic response with C1-INH in 50 % of patients with severe ACEI AAE.

1 Bas, Murat, et al. "Icatibant in ACE-Inhibitor–Induced Angioedema." New England Journal of Medicine N Engl J Med 372.19 (2015): 1866-868.